Pulmonary hypertension Historical Perspective

Pulmonary Hypertension Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pulmonary hypertension from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pulmonary hypertension Historical Perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Google Images
American Roentgen Ray Society Images of Pulmonary hypertension Historical Perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pulmonary hypertension Historical Perspective
CDC on Pulmonary hypertension Historical Perspective
Pulmonary hypertension Historical Perspective in the news
Blogs on Pulmonary hypertension Historical Perspective
Directions to Hospitals Treating Pulmonary hypertension
Risk calculators and risk factors for Pulmonary hypertension Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

The incidence of PAH associated with anorexigens is cyclical in nature and varies depending on the availability of specific appetite suppressants. The link was first identified in the 1960s when an epidemic of PAH occurred in Switzerland, Austria and Germany that was linked to the anorexigen aminorex fumarate. Use of the anorexigens fenfluramine and dexfenfluramine have also been linked with an increased risk for PAH.